Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next-generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens, has announced that it will report its fourth quarter and full year 2024 financial results on February 7, 2025. The company will host a conference call at 8:30 a.m. Eastern Time to discuss its financial results and provide an update on its business.



In the third quarter of 2024, Iterum reported cash, cash equivalents, and short-term investments of $14.5 million, which is expected to fund its operations into 2025, including through the repayment date of the 6.500% Exchangeable Notes due January 31, 2025. The company's research and development (R&D) expenses decreased significantly to $3.1 million from $14.9 million in the same period last year, primarily due to the completion of the REASSURE trial. General and administrative (G&A) expenses remained stable at $1.8 million. The net loss for the quarter was $6.1 million compared to $3.9 million in the same period last year.

Iterum's strategic process to maximize the value of sulopenem, its lead compound, is ongoing. The company has engaged a financial advisor to assist management and the board in evaluating strategic alternatives, such as selling, licensing, or otherwise disposing of its rights to the drug. This process is expected to help Iterum capitalize on the commercial potential of sulopenem and build a successful and sustainable business.



In addition to its financial results, Iterum is expected to provide updates on its ongoing clinical trials, regulatory developments, and potential partnerships or collaborations. The company's focus on developing next-generation antibiotics to combat multi-drug resistant pathogens positions it well to address the growing global health challenge of antibiotic resistance.



Investors and stakeholders will be closely watching Iterum's financial results and business updates, as the company continues to make progress in its mission to deliver differentiated anti-infectives aimed at combatting multi-drug resistant pathogens. The upcoming conference call and financial results report will provide valuable insights into Iterum's performance and future prospects.